Clinical trials: SARS-COV 2
COVID-19, SARS-CoV 2
Tannin Specific Natural Extract for COVID-19 Infection
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral…
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- TanCOVID (NCT04403646)
- Testing
- ARBOX
- Where
- Argentina
- Volunteers
- 124 people
- Sponsor
- Hospital de Clinicas José de San Martín
SARS CoV 2 Infection, COVID-19 Breakthrough
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St.
- Conditions
- SARS CoV 2 Infection, COVID-19 Breakthrough, COVID-19 Recurrent
- Trial name
- CoVICIS (NCT06435403)
- Where
- 2 sites in Ethiopia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04399980
- Testing
- Mavrilimumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
SARS CoV 2 Infection
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
Up to now, Corona Virus Disease 2019 (COVID-19) continues to spread rapidly around the world. From the beginning of the epidemic to the present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continuously…
- Trial name
- FASTER (NCT05244330)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
SARS-CoV Infection
Diode Laser 940 nm in Management of Loss of Taste Sensation
The global pandemic has recently emerged by transmission of SARS-CoV2 virus. The virus has had a massive impact on health, wealth and social aspects worldwide.
- Trial name
- NCT04821999
- Testing
- a 940-nm diode laser
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Fayoum University
SARS CoV 2 Infection
Impact of the Postponement of Surgery on Postoperative Morbidity After Sars-cov-2 Infection
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification in June 2021of previous recommendations concerning the postponing scheduled surgery suggesting local adaptations of this delay if epidemic…
- Trial name
- DROMIS-22 (NCT05336110)
- Testing
- Postponing surgery
- Where
- 40 sites in France
- Volunteers
- 5,189 people
- Sponsor
- Société Française d'Anesthésie et de Réanimation
SARS CoV 2 Infection
A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.
A phase IV study to assess if the SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen (J\&J) results in change in number and activation of platelets and anti-PF4 Level.
- Trial name
- NCT06360744
- Testing
- Johnson & Johnson
- Where
- 5 sites in Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jens D Lundgren, MD
SARS CoV 2 Infection, Alveolar; Injury
The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19
COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the…
- Conditions
- SARS CoV 2 Infection, Alveolar; Injury, Children, Pneumonia, Viral
- Trial name
- NCT05619640
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Haseki Training and Research Hospital
Coronavirus Infection, SARS-CoV 2
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults…
- Trial name
- NCT04447781
- Testing
- INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer
- Where
- 2 sites in South Korea
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
SARS-CoV 2, COVID-19
Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or…
- Trial name
- ERap-COV (NCT04405492)
- Testing
- Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling., Capillary and salivary sampling
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
SARS CoV 2 Infection, COVID-19
Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior
A study to investigate Rhinoswab as an alternative method to combined throat and deep nasal (CTDN) swab for respiratory sample collection in children who present to the Royal Children's Hospital (RCH) for viral testing.
- Trial name
- NCT05043623
- Testing
- Rhinoswab Junior, Combined nose and throat swab, Saliva swab
- Where
- Australia
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS CoV 2 Infection
Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study .
The objective is To evaluate the efficacy and safety of nasal spray and mouth spray application with hypochlorous acid-containing solution versus placebo as a curative treatment for hospitalized SARS-CoV-2 positive patients And…
- Trial name
- COVICONTROL (NCT05862480)
- Testing
- Spray with Hypochlorous Acid Group
- Where
- Tunisia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Monastir
Covid19, SARS-CoV 2 Infection
Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19
The goal of this study is to recruit confirmed Covid-19 patients, to evaluate whether the topical anti-septic can improve clinical outcome in early Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection.
- Trial name
- LT-COVID19 (NCT05049213)
- Testing
- Carrageenan nasal spray and 1% PVP- mouthwash and gargle
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- National Taiwan University Hospital
Covid19
suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the…
- Trial name
- SAVE-MORE (NCT04680949)
- Testing
- Anakinra
- Where
- 40 sites in Greece, Italy
- Volunteers
- 606 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
SARS-CoV 2
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies.
- Trial name
- AcNT-COVID19 (NCT04596098)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Grenoble
SARS-CoV 2, COVID-19
Convalescent Plasma Trial in COVID -19 Patients
Plasma therapy using convalescent plasma has been shown to be effective in severe acute respiratory syndrome, Ebola virus infection and in H1N1 influenza.
- Trial name
- NCT04356534
- Testing
- plasma therapy using convalescent plasma with antibody against SARS-CoV-2, Routine care for COVID-19 patients
- Where
- Bahrain
- Volunteers
- 40 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
COVID-19
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives
Coronavirus disease 2019 (COVID-19) ,caused by the newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has shown substantial global spread affecting over 2 million people and claiming over 120,000…
- Trial name
- NCT04357535
- Testing
- Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
- Where
- Saudi Arabia
- Volunteers
- 314 people
- Sponsor
- Hakeam Abdulaziz Hakeam
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV)
Transplacental Transmission of RSV (TTRSV)
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how this is moderated by other maternal infections during pregnancy Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins…
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Trial name
- NCT05443607
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tulane University
COVID-19 Disease
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An open label phase 2 trial to evaluate safety, tolerability and immunogenicity of the ABNCoV2 vaccine after intramuscular (IM) application.
- Trial name
- NCT05077267
- Testing
- ABNCoV2 100ug, ABNCoV2 50ug
- Where
- 2 sites in Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic